Reductions in AFP and PIVKA-II can predict the efficiency of anti-PD-1 immunotherapy in HCC patients

Reductions in AFP and PIVKA-II can predict the efficiency of anti-PD-1 immunotherapy in HCC patients

Abstract Background Few biomarkers can predict the efficiency of PD-1 blockade in patients with hepatocellular carcinoma (HCC). This study aimed to investigate the prognostic role of AFP and PIVKA-II in HCC patients receiving anti-PD-1 immunotherapy. Methods A total of 235 HCC patients treated with...

Full description

Bibliographic Details
Main Authors: Xuqi Sun, Jie Mei, Wenping Lin, Ziliang Yang, Wei Peng, Jinbin Chen, Yaojun Zhang, Li Xu, Minshan Chen
Format: Article
Language:English
Published: BMC 2021-07-01
Series:BMC Cancer
Subjects:
Hepatocellular carcinoma
AFP
PIVKA-II
Immunotherapy
Survival
Online Access:https://doi.org/10.1186/s12885-021-08428-w

Internet

https://doi.org/10.1186/s12885-021-08428-w

Similar Items